#United States #Tokyo #Health Innovation #Corundum Systems #Microbiome Research

Corundum Systems Biology Expands Presence in U.S. with New Executives

Corundum Systems Biology (CSB), an investment powerhouse committed to pioneering advancements in systems biology, has strengthened its U.S. operations through the appointment of two highly regarded senior executives. Dr. Henry Haiser, previously an Associate Scientific Director at Takeda Pharmaceuticals, will serve as Operating Partner, while Dr. Rotem Gura-Sadovsky, who has a rich background in systems biology and data science, steps in as Senior Director, Head of Data Strategy.

This strategic move not only reinforces CSB's leadership team but also significantly boosts their capabilities in evaluating cutting-edge technologies, refining investment strategies, and accelerating the development of transformative healthcare solutions. With the growing importance of microbiome research in biotechnology, these acquisitions are pivotal for CSB's ambition to remain at the forefront of innovation in public health.

Hidehiko Otake, the CEO of CSB, expressed enthusiasm about the new appointments, stating, “The addition of Dr. Haiser and Dr. Gura-Sadovsky enhances our leadership team and highlights our commitment to advancing novel health technologies.” He believes their expertise will be critical as CSB seeks to identify and support ventures in the U.S. that aim to make significant impacts in systems biology.

Dr. Haiser, with over ten years of experience in pharmaceutical drug discovery, notably established a pivotal microbiome discovery platform at Novartis Institutes for Biomedical Research. His prior work involved identifying and characterizing bioactive small molecules resulting from gut microbiome activities, progressing several programs through to Phase 2 clinical trials. At CSB, Dr. Haiser is set to work closely with portfolio companies, harnessing his scientific acumen and strategic vision to transition from foundational research to real-world applications.

“I’m looking forward to meeting with the minds behind the next generation of microbiome therapies and helping shape the future of the systems biology industry,” Dr. Haiser commented.

Joining Dr. Haiser, Dr. Gura-Sadovsky brings extensive knowledge from his previous roles at Finch Therapeutics and Enveda Biosciences, focusing on AI, machine learning, and big data analytics within the biotechnology sector. His work has facilitated the discovery of natural products from medicinal flora and led to the integration of multi-omics data to develop new diagnostic measures. His mission at CSB will focus on refining the data science strategies integral to advancing health innovations.

“Joining CSB provides an exciting opportunity to work with scientists at the forefront of health innovation,” Dr. Gura-Sadovsky noted, expressing eagerness to support the development of new microbiome solutions and integrative therapies.

About Corundum Systems Biology
Corundum Systems Biology is on a mission to facilitate groundbreaking advancements in human health by actively supporting innovative companies in the field of systems biology. Their commitment to nurturing the long-term success of portfolio companies is matched by their unique expertise, extensive industry connections, and access to vital health data. For updates, visit their LinkedIn or the official website CSB.

As CSB positions itself for a transformative phase in systems biology, the integration of seasoned professionals like Dr. Haiser and Dr. Gura-Sadovsky suggests a robust strategy aimed at impacting the biopharma landscape significantly. Their insights and strategies could lead to health solutions that not only address current challenges but also pave the way for future innovations in the healthcare sector.